Voyager Therapeutics Inc (VYGR)
8.43
-0.20
(-2.32%)
USD |
NASDAQ |
May 17, 16:00
8.43
0.00 (0.00%)
After-Hours: 20:00
Voyager Therapeutics Enterprise Value: 58.97M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 58.97M |
| May 16, 2024 | 69.85M |
| May 15, 2024 | 66.59M |
| May 14, 2024 | 61.69M |
| May 13, 2024 | 61.69M |
| May 10, 2024 | 59.51M |
| May 09, 2024 | 59.51M |
| May 08, 2024 | 66.59M |
| May 07, 2024 | 77.42M |
| May 06, 2024 | 86.66M |
| May 03, 2024 | 79.59M |
| May 02, 2024 | 64.36M |
| May 01, 2024 | 55.12M |
| April 30, 2024 | 25.75M |
| April 29, 2024 | 23.03M |
| April 26, 2024 | 14.87M |
| April 25, 2024 | 3.993M |
| April 24, 2024 | 12.15M |
| April 23, 2024 | 16.50M |
| April 22, 2024 | 12.15M |
| April 19, 2024 | 8.344M |
| April 18, 2024 | 11.06M |
| April 17, 2024 | 21.40M |
| April 16, 2024 | 34.45M |
| April 15, 2024 | 48.59M |
| Date | Value |
|---|---|
| April 12, 2024 | 58.93M |
| April 11, 2024 | 77.96M |
| April 10, 2024 | 80.68M |
| April 09, 2024 | 94.82M |
| April 08, 2024 | 93.19M |
| April 05, 2024 | 107.22M |
| April 04, 2024 | 96.36M |
| April 03, 2024 | 108.31M |
| April 02, 2024 | 138.72M |
| April 01, 2024 | 172.94M |
| March 31, 2024 | 106.13M |
| March 28, 2024 | 274.66M |
| March 27, 2024 | 288.24M |
| March 26, 2024 | 313.22M |
| March 25, 2024 | 271.95M |
| March 22, 2024 | 258.37M |
| March 21, 2024 | 279.55M |
| March 20, 2024 | 331.14M |
| March 19, 2024 | 315.39M |
| March 18, 2024 | 262.72M |
| March 15, 2024 | 273.03M |
| March 14, 2024 | 264.89M |
| March 13, 2024 | 265.43M |
| March 12, 2024 | 262.72M |
| March 11, 2024 | 261.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-38.66M
Minimum
Sep 29 2021
710.15M
Maximum
Jul 03 2019
141.86M
Average
116.24M
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.235B |
| Stereotaxis Inc | 161.38M |
| United Therapeutics Corp | 10.06B |
| MEI Pharma Inc | -35.56M |
| Agios Pharmaceuticals Inc | 1.352B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.33M |
| Revenue (Quarterly) | 19.52M |
| Total Expenses (Quarterly) | 35.70M |
| EPS Diluted (Quarterly) | -0.20 |
| Profit Margin (Quarterly) | -58.05% |
| Earnings Yield | -1.30% |
| Normalized Earnings Yield | -1.305 |